Mohammed A. Alghamdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed A. Alghamdi has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Abdulaziz R. Al Johni
Department of Laboratory at King Fahad Hospital , Madinah , Saudi Arabia
1 shared publication - Abdullah A. Khan Ghyathuddin
Department of Biological Sciences, Faculty of Science, King Abdulaziz University
1 shared publication - Adam Brufsky
University of Pittsburgh, Pittsburgh, PA
1 shared publication - Alaa A. A. Aljabali
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan
1 shared publication Amos Lal
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
1 shared publicationBruce D. Uhal
Department of Physiology, Michigan State University, East Lansing, MI 48824, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 20 (1) , 20251076
Oncolytic bacteria: A revolutionary approach to cancer therapy
Cancer is one of the most devastating diseases all over the globe, and it is the second worldwide cause of death, exceeded only by cardiovascular diseases. The therapeutic approach to human cancer has evolved significantly and has varied depending on the type and stage of cancer, as well as the general health status of the patient. Despite the advancements in cancer treatment, various challenges persist in the treatment of cancer, including side effects, drug resistance, and incomplete eradication of tumors. The use of oncolytic bacteria (cancer targeting and destroying bacteria) has been identified to have several advantages over the traditional methods of cancer treatment. Several bacterial species have been identified to be used in the treatment of different types of cancers. Oncolytic therapy can be achieved through the use of a naturally occurring and/or genetically modified bacterial species, including Clostridium , Salmonella, Escherichia coli, and Listeria spp. with their toxins, enzymes, biofilms, and secondary metabolites as well as their spores that leads to direct or indirect killing of cancer cells. This review provides some highlights about the biology and therapeutic potential of oncolytic bacteria individually or in combination with other therapeutic approaches against different types of cancers. Besides, the current challenges and future perspectives will be explored.
- 1 January 2025
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 20 (1) , 20251076
Open AccessOncolytic bacteria: A revolutionary approach to cancer therapy
Cancer is one of the most devastating diseases all over the globe, and it is the second worldwide cause of death, exceeded only by cardiovascular diseases. The therapeutic approach to human cancer has evolved significantly and has varied depending on the type and stage of cancer, as well as the general health status of the patient. Despite the advancements in cancer treatment, various challenges persist in the treatment of cancer, including side effects, drug resistance, and incomplete eradication of tumors. The use of oncolytic bacteria (cancer targeting and destroying bacteria) has been identified to have several advantages over the traditional methods of cancer treatment. Several bacterial species have been identified to be used in the treatment of different types of cancers. Oncolytic therapy can be achieved through the use of a naturally occurring and/or genetically modified bacterial species, including Clostridium , Salmonella, Escherichia coli, and Listeria spp. with their toxins, enzymes, biofilms, and secondary metabolites as well as their spores that leads to direct or indirect killing of cancer cells. This review provides some highlights about the biology and therapeutic potential of oncolytic bacteria individually or in combination with other therapeutic approaches against different types of cancers. Besides, the current challenges and future perspectives will be explored.
- 1 October 2021
- Published by Elsevier in Autoimmunity Reviews
- Vol. 20 (10) , 102909
The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19
- 1 October 2021
- Published by Elsevier in Autoimmunity Reviews
- Vol. 20 (10) , 102909
The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19